This particle is not required to combine with any adjuvant STING agonist, but based on the Mn2+ stimulation activity on STING itself, its combination with the model antigen ovalbumin (OVA) demonstrates superior STING-dependent innate immunity to B16-OVA melanoma [119]. Here, STING1 is linked to melanoma.